Table 2.

Prevalence of subretinal fluid at each visit between two groups.

	Aflibercept	Brolucizumab	p-Value
	(n = 38)	(n = 14)
Baseline SRF (%)	38 (100%)	14 (100%)	1.0
SRF at 1-month visit (%) 95%CI	21 (55.3%) 38.7–71.8%	5 (35.7%) 7.0–64.4%	0.35
SRF at 2-month visit (%) 95%CI	9 (23.7%) 9.5–37.9%	2 (14.3%) 0–35.3%	0.72
SRF at 3-month visit (%) 95%CI	6 (15.8%) 3.6–27.9%	0 (0%) 0%	0.27

SRF: subretinal fluid.